JP2017537985A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537985A5
JP2017537985A5 JP2017550469A JP2017550469A JP2017537985A5 JP 2017537985 A5 JP2017537985 A5 JP 2017537985A5 JP 2017550469 A JP2017550469 A JP 2017550469A JP 2017550469 A JP2017550469 A JP 2017550469A JP 2017537985 A5 JP2017537985 A5 JP 2017537985A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
plga
composition according
polymer
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537985A (ja
JP6882186B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065894 external-priority patent/WO2016100392A1/en
Publication of JP2017537985A publication Critical patent/JP2017537985A/ja
Publication of JP2017537985A5 publication Critical patent/JP2017537985A5/ja
Priority to JP2021078406A priority Critical patent/JP2021119183A/ja
Application granted granted Critical
Publication of JP6882186B2 publication Critical patent/JP6882186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550469A 2014-12-15 2015-12-15 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 Active JP6882186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078406A JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092118P 2014-12-15 2014-12-15
US62/092,118 2014-12-15
US201562139306P 2015-03-27 2015-03-27
US62/139,306 2015-03-27
PCT/US2015/065894 WO2016100392A1 (en) 2014-12-15 2015-12-15 Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078406A Division JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Publications (3)

Publication Number Publication Date
JP2017537985A JP2017537985A (ja) 2017-12-21
JP2017537985A5 true JP2017537985A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-31
JP6882186B2 JP6882186B2 (ja) 2021-06-02

Family

ID=55069169

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017550467A Active JP6847848B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤、及び緑内障の治療におけるその使用方法
JP2017550469A Active JP6882186B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
JP2021078406A Pending JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017550467A Active JP6847848B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤、及び緑内障の治療におけるその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078406A Pending JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Country Status (19)

Country Link
US (4) US20170273901A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3233058A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP6847848B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR20170094793A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN107205940A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2015362621B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112017012706A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2972075C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO2017007003A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201791337A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1243942A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL252943A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2017007873A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ733130A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12017501097A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2729731C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201704869VA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO2016100392A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201703875B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US11180760B2 (en) * 2012-03-09 2021-11-23 The Johns Hopkins University Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
BR112017012706A2 (pt) * 2014-12-15 2018-03-13 The Johns Hopkins University formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares
CA2999766A1 (en) 2015-09-22 2017-03-30 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
WO2017083779A1 (en) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggregating microparticles for therapy
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
CA3104513A1 (en) * 2018-06-25 2020-01-02 Titan Pharmaceuticals, Inc. Implants for release of lipophilic or amphiphilic pharmaceutical substances
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
TW202035364A (zh) * 2018-09-27 2020-10-01 美商灰色視覺公司 用於眼部遞送之化合物及組合物
CN110946858A (zh) * 2018-09-27 2020-04-03 中国科学院上海生命科学研究院 吲哚满酮衍生物在治疗肥胖及其相关疾病中的应用
KR102308227B1 (ko) * 2018-10-31 2021-10-05 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 정제 조성물
KR102322429B1 (ko) * 2018-10-31 2021-11-08 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법
WO2020102758A1 (en) * 2018-11-15 2020-05-22 Graybug Vision, Inc. Improved aggregated microparticles
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
US11471412B1 (en) 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN110833425B (zh) * 2019-11-27 2022-12-30 佛山科学技术学院 一种用于鸡胚采血的血管托持器
WO2021113662A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
KR20240025990A (ko) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물
KR20240028815A (ko) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물
EP4611814A1 (en) 2022-11-04 2025-09-10 Semmelweis Egyetem In vivo targeting of therapeutic molecules to the retina via the optical system of the eye

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4991920A (en) 1988-12-27 1991-02-12 Andrzej Peczalski Optical converter
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5441722A (en) 1994-02-18 1995-08-15 Merck & Co., Inc. Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
AU2707500A (en) 1998-12-04 2000-06-26 Incept Llc Biocompatible crosslinked polymers
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CA2621395A1 (en) * 2005-09-07 2007-03-15 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8663674B2 (en) 2006-01-13 2014-03-04 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
JP2010502713A (ja) 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
PL2091514T3 (pl) 2006-11-09 2014-03-31 Alcon Res Ltd Nierozpuszczalna w wodzie matryca polimerowa do dostarczania leku
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
EP2121057A4 (en) 2007-02-06 2012-10-10 Incept Llc POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
CN101081206A (zh) * 2007-06-29 2007-12-05 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌药物组合物
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
AU2008315318B2 (en) 2007-10-26 2014-02-06 National Institute Of Immunology Biodegradable polymer scaffold and process for preparation thereof
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
CA2717133C (en) 2008-02-29 2016-04-26 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
CN101336890A (zh) 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
US20100063135A1 (en) 2008-09-10 2010-03-11 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
WO2010079496A2 (en) 2009-01-12 2010-07-15 Hadasit Medical Research Services & Development Limited Tissue regeneration membrane
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
CA2753690A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
GB0903810D0 (en) 2009-03-05 2009-04-22 Regentec Ltd Delivery system
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP3960215B1 (en) 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
US8889193B2 (en) * 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2011109384A2 (en) 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
EP2550263A4 (en) 2010-03-23 2013-07-24 Univ Johns Hopkins COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2011119995A2 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA2816977C (en) 2010-11-05 2019-10-29 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
WO2012112674A2 (en) * 2011-02-15 2012-08-23 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
WO2013090804A2 (en) 2011-12-14 2013-06-20 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
WO2013110028A1 (en) 2012-01-19 2013-07-25 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013256092B2 (en) * 2012-05-03 2017-11-23 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
JP2017512748A (ja) * 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC スニチニブを含んでいる眼科用局所医薬組成物
EP2895146A1 (en) * 2012-09-17 2015-07-22 BIND Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN103848985B (zh) * 2012-11-30 2018-03-02 杨子剑 含有舒尼替尼类似物结构的新化合物以及制备方法和用途
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN104208715B (zh) 2013-05-31 2016-12-28 天津键凯科技有限公司 具有提高的药物生物活性的低分子量聚乙二醇药物结合物
JP5698882B1 (ja) 2013-06-18 2015-04-08 昭和電工株式会社 コンデンサ陽極体およびその製造方法
US10646027B2 (en) 2013-08-29 2020-05-12 Sayeeda Mazed Multifunctional personal care devices/apparatuses and compositions for hair or skin
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
KR101564401B1 (ko) 2014-04-10 2015-11-02 한국화학연구원 브린졸아마이드의 제조방법
WO2016025215A1 (en) 2014-08-13 2016-02-18 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
WO2016060925A1 (en) 2014-10-16 2016-04-21 Incept, Llc Ocular gels or hydrogels and microinjectors
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
AU2015360469B2 (en) 2014-12-10 2021-03-25 Incept, Llc Hydrogel drug delivery implants
BR112017012706A2 (pt) * 2014-12-15 2018-03-13 The Johns Hopkins University formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares
JP6479485B2 (ja) 2015-01-15 2019-03-06 大内新興化学工業株式会社 眼疾患治療用ナノ粒子製剤
CN107206099A (zh) 2015-01-20 2017-09-26 约翰霍普金斯大学 用于持续释放抗青光眼剂以控制眼内压的组合物
MX385405B (es) 2015-05-05 2025-03-18 Eyepoint Pharmaceuticals Us Inc Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
JP2018515529A (ja) 2015-05-12 2018-06-14 インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc ハイドロゲルからの薬物送達
CN107949354B (zh) 2015-07-22 2022-02-18 因赛普特有限责任公司 涂覆的泪点塞
BR112018010671A8 (pt) 2015-11-25 2019-02-26 Incept Llc dispositivos e métodos de distribuição de fármaco com mudança de forma

Similar Documents

Publication Publication Date Title
JP2017537985A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2018500394A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
Kompella et al. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kamaleddin Nano-ophthalmology: Applications and considerations
RU2017123358A (ru) Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
JP2016521712A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
JP2014533698A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
HRP20230510T1 (hr) Farmaceutski pripravak dasatinib
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
JP2016528202A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
HRP20210577T1 (hr) Sastavi i načini liječenja i sprječavanje upale
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
JP2015526467A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013542205A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015520241A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2016011297A3 (en) Methods and related compositions for improved drug bioavailability and disease treatment
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
JP2017512194A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2006088134A1 (ja) ステロイド化合物の副作用軽減または回避方法
JP2017525758A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)